Opko Health Stock Price, News & Analysis

OPKO Health (NASDAQ: OPK) will report its operating and financial results for Q2 2022 on August 4, 2022, after U.S. markets close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results and provide financial guidance. Investors are encouraged to pre-register for easier access to the call. A replay of the conference call will be available until August 11, 2022. OPKO is focused on establishing industry-leading positions in rapidly growing markets through its innovative biopharmaceutical and diagnostics expertise.

OPKO Health, Inc. (NASDAQ: OPK) will participate in the 2022 Jefferies Healthcare Conference from June 8-10 in New York City. Management's fireside chat is scheduled for June 9 at 8:00 a.m. Eastern time, and it will be webcast live, with a replay available on OPKO’s website. This event highlights OPKO's commitment to engaging with investors and showcasing its innovative biopharmaceutical and diagnostics initiatives.

OPKO Health, Inc. (NASDAQ: OPK) reported its financial results for Q1 2022, revealing consolidated revenues of $329.2 million, down from $545.2 million in Q1 2021. The company incurred a net loss of $55.4 million, or $0.08 per share, compared to a net income of $31.1 million in the previous year. Key business highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and the sale of GeneDx to Sema4, which provided $150 million in cash proceeds. Notably, OPKO expects to receive $85 million in milestone payments from Pfizer in Q2 2022.

OPKO Health, Inc. (NASDAQ: OPK) has acquired ModeX Therapeutics for $300 million in OPKO common stock, significantly enhancing its product pipeline. Notable appointments include Dr. Elias Zerhouni as President and Vice Chairman, Dr. Gary Nabel as Chief Innovation Officer, and Alexis Borisy as a Board member. ModeX specializes in innovative immune therapies for cancer and infectious diseases using multi-specific antibody technologies. This acquisition aims to leverage synergies in OPKO's diagnostics and therapeutics portfolio, potentially improving patient outcomes and accelerating product development.

OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. The company's senior management will discuss the results and provide financial guidance during a live conference call at 4:30 PM ET. Participants can pre-register for the call and access a webcast on OPKO's Investor Relations page. A replay will be available until May 16, 2022. For further information about OPKO's operations and market position, visit their official website.

GeneDx, Inc. has published research highlighting the importance of genomic data sharing for identifying gene-disease relationships. This initiative, facilitated through GeneMatcher, has resulted in over 200 new associations of disease-gene links in just three years. The findings were published in Human Mutation, demonstrating how collaboration between clinicians and researchers can accelerate diagnosis for rare diseases. GeneDx's extensive database of over 300,000 clinical exomes plays a crucial role in these developments, significantly impacting patient diagnostics and advancing precision medicine.

Saol Therapeutics has announced a collaboration with GeneDx to identify patients with Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare mitochondrial disease affecting fewer than 300 children annually in the U.S. The partnership aims to increase recruitment for a Phase 3 clinical trial testing dichloroacetate (DCA), which has Orphan Product designation from the FDA for congenital lactic acidosis. The trial is crucial as PDCD currently lacks FDA-approved treatments. Dr. Peter Stacpoole emphasizes the importance of the collaboration for effective patient recruitment.

OPKO Health, Inc. (NASDAQ: OPK) announced its fourth quarter 2021 financial results with total revenues of $401.3 million, down from $494.6 million in Q4 2020. The company reported a net loss of $73.8 million, or $0.11 per share, compared to net income of $32.3 million a year prior. Key highlights include NGENLA® receiving regulatory approvals in multiple countries and RAYALDEE® launched in Germany. OPKO has entered a definitive agreement for Sema4 to acquire GeneDx for a potential total consideration of $623 million.

OPKO Health, Inc. (NASDAQ: OPK) is set to release its financial results for the quarter ended December 31, 2021, post-market on February 24, 2022. The company will also provide a business update and financial guidance during a conference call at 4:30 p.m. Eastern on the same day. Investors can pre-register for the call or access it via a live audio webcast. The call aims to discuss operating metrics and future outlook. For more details about OPKO's strategies and market position, visit their website.